132 related articles for article (PubMed ID: 8879978)
21. Use of cellular electrical impedance sensing to assess in vitro cytotoxicity of anticancer drugs in a human kidney cell nephrotoxicity model.
Xie F; Xu Y; Wang L; Mitchelson K; Xing W; Cheng J
Analyst; 2012 Mar; 137(6):1343-50. PubMed ID: 22214987
[TBL] [Abstract][Full Text] [Related]
22. Atractyloside nephrotoxicity: in vitro studies with suspensions of rat renal fragments and precision-cut cortical slices.
Obatomi DK; Bach PH
In Vitr Mol Toxicol; 2000; 13(1):25-36. PubMed ID: 10900405
[TBL] [Abstract][Full Text] [Related]
23. Scavenging activity of indole compounds against cisplatin-induced reactive oxygen species.
Fukutomi J; Fukuda A; Fukuda S; Hara M; Terada A; Yoshida M
Life Sci; 2006 Dec; 80(3):254-7. PubMed ID: 17049361
[TBL] [Abstract][Full Text] [Related]
24. The immediate early genes, c-fos, c-jun and AP-1, are early markers of platinum analogue toxicity in human proximal tubular cell primary cultures.
Wainford RD; Weaver RJ; Hawksworth GM
Toxicol In Vitro; 2009 Aug; 23(5):780-8. PubMed ID: 19383537
[TBL] [Abstract][Full Text] [Related]
25. Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity.
Liu L; Yang C; Herzog C; Seth R; Kaushal GP
Biochem Pharmacol; 2010 Jan; 79(2):137-46. PubMed ID: 19699182
[TBL] [Abstract][Full Text] [Related]
26. Cells of proximal and distal tubular origin respond differently to challenges of oxalate and calcium oxalate crystals.
Thamilselvan S; Hackett RL; Khan SR
J Am Soc Nephrol; 1999 Nov; 10 Suppl 14():S452-6. PubMed ID: 10541282
[TBL] [Abstract][Full Text] [Related]
27. Role of cysteine S-conjugate beta-lyase in the metabolism of cisplatin.
Zhang L; Hanigan MH
J Pharmacol Exp Ther; 2003 Sep; 306(3):988-94. PubMed ID: 12750429
[TBL] [Abstract][Full Text] [Related]
28. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats.
Uehara T; Watanabe H; Itoh F; Inoue S; Koshida H; Nakamura M; Yamate J; Maruyama T
Arch Toxicol; 2005 Aug; 79(8):451-60. PubMed ID: 15856183
[TBL] [Abstract][Full Text] [Related]
29. New platinum complex compounds with reduced nephrotoxicity discovered in long-term histoculture of human renal cortical tissue.
Chang SG; Kwon DU; Kim JI; Jung JC; Rho YS; Hoffman RM
Anticancer Res; 1995; 15(3):675-81. PubMed ID: 7645942
[TBL] [Abstract][Full Text] [Related]
30. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
Ali BH; Al Moundhri MS
Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908
[TBL] [Abstract][Full Text] [Related]
31. DNA damage, gadd153 expression, and cytotoxicity in plateau-phase renal proximal tubular epithelial cells treated with a quinol thioether.
Jeong JK; Dybing E; Søderlund E; Brunborg G; Holme JA; Lau SS; Monks TJ
Arch Biochem Biophys; 1997 May; 341(2):300-8. PubMed ID: 9169019
[TBL] [Abstract][Full Text] [Related]
32. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
33. Primary porcine proximal tubular cells as a model for transepithelial drug transport in human kidney.
Schlatter P; Gutmann H; Drewe J
Eur J Pharm Sci; 2006 May; 28(1-2):141-54. PubMed ID: 16510270
[TBL] [Abstract][Full Text] [Related]
34. Cytotoxicity of different platinum (II) analogues to human tumour cell lines in vitro and murine tumour in vivo alone or combined with electroporation.
Cemazar M; Pipan Z; Grabner S; Bukovec N; Sersa G
Anticancer Res; 2006; 26(3A):1997-2002. PubMed ID: 16827135
[TBL] [Abstract][Full Text] [Related]
35. Comparative nephrotoxicity of cisplatin and new octahedral Pt(IV) complexes.
Kim WK; Kwon YE
Cancer Chemother Pharmacol; 2007 Jul; 60(2):237-43. PubMed ID: 17089165
[TBL] [Abstract][Full Text] [Related]
36. Role of lipid peroxidation and poly(ADP-ribose) polymerase activation in oxidant-induced membrane transport dysfunction in opossum kidney cells.
Min SK; Kim SY; Kim CH; Woo JS; Jung JS; Kim YK
Toxicol Appl Pharmacol; 2000 Aug; 166(3):196-202. PubMed ID: 10906283
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin and oxaliplatin cytotoxic effects in sensitive and cisplatin-resistant human cervical tumor cells: time and mode of application dependency.
Martelli L; Ragazzi E; Di Mario F; Basato M; Martelli M
Anticancer Res; 2009 Oct; 29(10):3931-7. PubMed ID: 19846931
[TBL] [Abstract][Full Text] [Related]
38. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
Robson H; Meyer S; Shalet SM; Anderson E; Roberts S; Eden OB
Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980
[TBL] [Abstract][Full Text] [Related]
39. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
Holzer AK; Manorek GH; Howell SB
Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
[TBL] [Abstract][Full Text] [Related]
40. Stress response inhibits the nephrotoxicity of cisplatin.
Hanigan MH; Deng M; Zhang L; Taylor PT; Lapus MG
Am J Physiol Renal Physiol; 2005 Jan; 288(1):F125-32. PubMed ID: 15353400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
